News
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Digital Bridge Between the Brain and Spine: How an Implant Restored Walking Ability to a Paralyzed Patient − Case Study
When a spinal cord injury occurs, communication between the brain and peripheral nerves is…
A Cloned Monkey Survived to Adulthood for the First Time. Will We Soon Be Able to Clone Humans?
A macaque named ReTro, born as a result of a cloning experiment by Chinese scientists, has reached…
Can we properly manage osteoporotic fractures?
Osteoporotic fractures are associated with increased morbidity and mortality and often lead to an…
Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin…
Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Lurasidone is an effective and very gentle antipsychotic which is establishing a prominent position…
Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism
Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75…
Generic Substitution of Levothyroxine in Practice
The active ingredient levothyroxine is found in a significant number of medicinal products (MP) in…
Options for Systemic Therapy of Advanced Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is the most aggressive type of lung tumor. Although it responds well…
Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
In September 2023, experts from Miami Cancer Institute published their consensus statement on the…